| Literature DB >> 35392822 |
Min Xu1, Hui Chen1, Hong-Wei Li2,3.
Abstract
BACKGROUND: The SYNTAX score affects clinical outcomes in early studies. However, the prognostic value of the SYNTAX Score for long-term outcomes and differences by SYNTAX score risk stratification in long-term prognosis between medical therapy and percutaneous coronary intervention (PCI) in patients with unstable angina pectoris (UAP) are not well known in the era of new generation drug-eluting stents and medication.Entities:
Keywords: Coronary heart disease; Major adverse cardiovascular events; SYNTAX score; Unstable angina pectoris
Mesh:
Year: 2022 PMID: 35392822 PMCID: PMC8991808 DOI: 10.1186/s12872-022-02604-x
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Study design
Baseline characteristics by SYNTAX score
| SYNTAX score ≤ 22 (N = 1695) | SYNTAX score 23–32 (N = 432) | SYNTAX score ≥ 33 (N = 237) | ||
|---|---|---|---|---|
| Age in years (mean, SD) | 64.50 ± 9.72 | 65.79 ± 9.99a | 66.34 ± 10.20a | < |
| Male, n (%) | 989 (58.3) | 273 (63.2) | 170 (71.7)a,b | < |
| History of smoking, n (%) | 779 (46.0) | 226 (52.3)a | 135 (57.0)a | < |
| Hypertension, n (%) | 1225 (72.3) | 325 (75.2) | 171 (72.2) | 0.454 |
| Diabetes mellitus, n (%) | 571 (33.7) | 190 (44.0)a | 115 (48.5)a | < |
| Family history of CHD, n (%) | 455 (26.8) | 117 (27.1) | 53 (22.4) | 0.323 |
| Previous MI, n (%) | 104 (6.1) | 53 (12.3)a | 33 (13.9)a | < |
| Atrial fibrillation, n (%) | 98 (5.8) | 22 (5.1) | 8 (3.4) | 0.293 |
| Chronic kidney disease, n (%) | 164 (9.7) | 60 (13.9) | 39 (16.5) | < |
| Prior stroke, n (%) | 265 (15.6) | 73 (16.9) | 45 (19.0) | 0.385 |
| Prior PAD, n (%) | 129 (7.6) | 34 (7.9) | 27 (11.4) | 0.132 |
| Heart failure, n (%) | 77 (4.5) | 33 (7.6)a | 23 (9.7)a | < |
| LVEF (%) | 67 ± 7 | 65 ± 9a | 64 ± 8a,b | < |
| BMI (kg/m2) | 25.93 ± 3.51 | 25.77 ± 3.53 | 25.74 ± 3.48 | 0.563 |
| FPG (mmol/L) | 5.73 ± 1.65 | 6.25 ± 2.27a | 6.53 ± 2.14a | < |
| Triglyceride (mmol/L) | 1.63 ± 1.15 | 1.65 ± 0.99 | 1.65 ± 1.13 | 0.897 |
| Total cholesterol (mmol/L) | 4.29 ± 1.02 | 4.41 ± 1.14 | 4.42 ± 1.11 | 0.050 |
| HDL-C (mmol/L) | 1.15 ± 0.28 | 1.12 ± 0.27 | 1.12 ± 0.25 | 0.069 |
| LDL-C (mmol/L) | 2.42 ± 0.74 | 2.51 ± 0.81a | 2.54 ± 0.79a | < |
| Serum uric acid (umol/L) | 339.56 ± 82.94 | 342.54 ± 83.10 | 345.81 ± 88.26 | 0.430 |
| hs-CRP (mg/L) | 3.26 ± 5.46 | 4.07 ± 6.72a | 4.79 6.83a | < |
CHD Coronary heart disease, MI myocardial infarction, FPG fasting plasma glucose, PAD peripheral arterial disease, LVEF left ventricular ejection fraction, BMI body mass index, HDL-C low density lipoprotein cholesterol-C, LDL-C low density lipoprotein cholesterol-C, hs-CRP high-sensitivity C-reactive protein, Italic values indicate statistical significance
aCompare with low SYNTAX score
bCOMPARE with medium SYNTAX score
PCI versus medical therapy in baseline characteristics
| Medical therapy group (n = 1018) | PCI group (n = 1346) | ||
|---|---|---|---|
| Age in years | 65.6 ± 9.6 | 64.4 ± 10.0 | < |
| Male, n (%) | 562 (55.2) | 870 (64.6) | < |
| History of smoking, n (%) | 442 (43.4) | 698 (51.9) | < |
| Hypertension, n (%) | 769 (75.5) | 1004 (74.6) | 0.598 |
| Diabetes mellitus, n (%) | 368 (36.1) | 573 (42.6) | < |
| Family history of CHD, n (%) | 270 (26.5) | 355 (26.4) | 0.936 |
| Previous MI, n (%) | 65 (6.4) | 125 (9.3) | < |
| Atrial fibrillation, n (%) | 73 (7.2) | 55 (4.1) | < 0.05 |
| Chronic kidney disease, n (%) | 114 (11.2) | 149 (11.1) | 0.992 |
| Prior stroke, n (%) | 153 (15.0) | 230 (17.1) | 0.179 |
| PAD, n (%) | 77 (7.6) | 113 (8.4) | 0.462 |
| Heart failure, n (%) | 55 (5.4) | 78 (5.8) | 0.682 |
| LVEF (%) | 67 ± 7 | 66 ± 8 | < |
| Heart rate (bpm) | 70.6 ± 11.2 | 70.8 ± 11.6 | 0.663 |
| BMI (kg/m2) | 25.84 ± 3.57 | 25.92 ± 3.47 | 0.577 |
| FPG (mmol/L) | 7.85 ± 3.18 | 8.38 ± 3.94 | < |
| Triglyceride (mmol/L) | 1.56 ± 1.16 | 1.68 ± 1.09 | < |
| Total cholesterol (mmol/L) | 4.27 ± 0.96 | 4.37 ± 1.11 | < |
| HDL-C (mmol/L) | 1.17 ± 0.27 | 1.12 ± 0.27 | < |
| LDL-C (mmol/L) | 2.39 ± 0.70 | 2.49 ± 0.79 | < |
| Serum uric acid (umol/L) | 335 ± 85 | 345 ± 82 | < |
| hs-CRP (mg/L) | 3.41 ± 5.78 | 3.67 ± 5.94 | 0.277 |
| SYNTAX score | 12.90 ± 9.33 | 21.04 ± 10.16 | < |
| Low SYNTAX score, n (%) | 889 (87.3) | 806 (59.9) | < |
| Medium SYNTAX score, n (%) | 81 (8.0) | 351 (26.1) | |
| High SYNTAX score, n (%) | 48 (4.7) | 189 (14.0) |
MI myocardial infarction, FPG fasting plasma glucose, PAD peripheral arterial disease, LVEF left ventricular ejection fraction, BMI Body mass index, HDL-C low density lipoprotein cholesterol-C, LDL-C low density lipoprotein cholesterol-C, PCI percutaneous coronary intervention, hs-CRP high-sensitivity C-reactive protein, Italic values indicate statistical significance
PCI versus medical therapy in long-term MACEs according to SYNTAX scores
| Overall | SYNTAX score ≤ 22 | SYNTAX score 23–32 | SYNTAX score ≥ 33 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical therapy ((n = 1018) | PCI (n = 1346) | Medical therapy (n = 889) | PCI (n = 806) | Medical therapy (n = 81) | PCI (n = 351) | Medical therapy (n = 48) | PCI (n = 189) | |||||
| MACEs, n (%) | 35 (3.4) | 60 (4.5) | 0.211 | 25 (2.8) | 32 (4.0) | 0.187 | 2 (2.5) | 14 (4.0) | 0.514 | 8 (16.7) | 14 (7.4) | 0.048 |
| All-cause death, n (%) | 27 (2.7) | 43 (3.2) | 0.411 | 18 (2.0) | 21 (2.6) | 0.426 | 2 (2.5) | 9 (2.6) | 0.961 | 7 (14.6) | 13 (6.9) | 0.086 |
| Cardiac death, n (%) | 13 (1.3) | 24(1.8) | 0.326 | 7 (0.8) | 13 (1.6) | 0.116 | 1 (1.2) | 4 (1.1) | 0.943 | 7 (14.6) | 7 (3.7) | 0.004 |
| Nonfatal MI, n (%) | 3 (0.3) | 6 (0.4) | 0.555 | 2 (0.2) | 3 (0.4) | 0.557 | 0 (0) | 2 (0.6) | 0.496 | 1 (2.1) | 1 (0.5) | 0.293 |
| Stroke, n (%) | 5 (0.5) | 11 (0.8) | 0.338 | 5 (0.6) | 8 (1.0) | 0.311 | 0 (0) | 3 (0.9) | 0.404 | 0 (0) | 0 (0) | |
MACE major adverse cardiovascular events, MI myocardial infarction, PCI percutaneous coronary intervention, P level of statistical significance
Fig. 2a Comparison of MACEs among SYNTAX Score risk stratification in medical therapy group. b Comparison of all-cause death among SYNTAX Score risk stratification in medical therapy group. c Comparison of cardiac death among SYNTAX Score risk stratification in medical therapy group
Fig. 3a Comparison of MACEs among SYNTAX Score risk stratification in PCI group. b Comparison of all-cause death among SYNTAX Score risk stratification in PCI group. c Comparison of cardiac death among SYNTAX Score risk stratification in PCI group
Predictors for long-term MACEs in patients underwent medical therapy or PCI
| Medication group | PCI group | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Age in years | 1.086 (1.037–61.136) | 0.000 | 1.096 (1.051–1.143) | < | 1.005 (0.975–1.036) | 0.749 | – | – |
| Male | 1.338 (0.549–3.266) | 0.522 | – | – | 1.483 (0.725–3.033) | 0.280 | – | – |
| History of smoking | 0.797 (0.314–2.026) | 0.634 | – | – | 0.776(0.410–1.466) | 0.434 | – | – |
| Hypertension | 0.883 (0.333–2.338) | 0.802 | – | – | 1.225 (0.652–2.302) | 0.529 | – | – |
| Diabetes mellitus | 3.181 (1.518–6.668) | 0.002 | 2.873 (1.412–5.846) | 0.004 | 0.916 (0.529–1.584) | 0.753 | – | – |
| Hyperlipidemia | 0.954 (0.461–1.973) | 0.899 | – | – | 0.697 (0.390–1.246) | 0.223 | – | – |
| Hyperuricemia | 1.907 (0.683–5.327) | 0.218 | – | – | 1.094 (0.563–2.126) | 0792 | – | – |
| Family history of CHD | 1.341 (0.4556–3.236) | 0.514 | – | – | 1.271 (0.682–2.369) | 0.451 | – | – |
| Previous MI | 1.237 (0.320–4.777) | 0.758 | – | – | 0.774 (0.344–1.742) | 0.537 | – | – |
| Atrial fibrillation | 0.561 (0.190–1.655) | 0.295 | – | – | 0.477 (0.178–1.274) | 0.140 | – | – |
| Chronic kidney disease | 1.848 (0.810–4.216) | 0.145 | – | 2.751 (1.418–5.334) | 0.003 | 2.998 (1.666–5.396) | < | |
| Prior stroke | 0.917 (0.358–2.353) | 0.857 | – | – | 1.824 (0.983–3.384) | 0.0757 | – | – |
| PAD | 0.829 (0.270–2.548) | 0.744 | – | – | 1.429 (0.504–4.053) | 0.502 | – | – |
| LVEF | 0.010 (0.000–0.766) | 0.000 | 0.017 (0.000–0.645) | 0.028 | 0.023 (0.002–0.344) | 0.006 | 0.009 (0.001–0.085) | < |
| SYNTAX ≥ 33 | 4.895 (1.840–13.017) | 0.001 | 4.912 (2.108–11.449) | < | 1.666 (0.889–3.119) | 0.111 | – | – |
| BMI | 0.966 (0.868–1.075) | 0.523 | – | – | 0.950 (0.875–1.032) | 0.226 | – | – |
| Heart rate | 1.010 (0.984–1.038) | 0.457 | – | – | 0.992 (0.970–1.015) | 0.490 | – | – |
| hs-CRP | 1.033 (0.997–1.071) | 0.075 | 1.046 (1.010–1.083) | 0.011 | 1.018 (0.985–1.052) | 0.289 | – | – |
CHD coronary heart disease, MI Myocardial infarction, FPG fasting plasma glucose, PAD peripheral arterial disease, LVEF left ventricular ejection fraction, BMI body mass index, PCI percutaneous coronary intervention, hs-CRP: high-sensitivity C-reactive protein, Italic values indicate statistical significance
Hosmer–Lemeshow test for the model of predictors for long-term MACEs
| Chi-square | |||
|---|---|---|---|
| Medication group | 12.527 | 8 | 0.129 |
| PCI group | 8.426 | 7 | 0.297 |
PCI Percutaneous coronary intervention, P level of statistical significance